Prostate Health Index for Prostate Cancer Diagnosis

Completed

• Conditions: Prostate Cancer
• Interventions: Device: Measurement of Prostate Health Index (PHI)

• Registration Number: NCT03151356
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Prostate biopsies are the gold standard for prostate cancer (PCa) diagnosis. They are performed according to the results of the measurement of prostate-specific antigen (PSA) in the serum of patients with PCa suspicion. More than half of the prostate biopsies reveal eventually negative because of the poor specificity of prostate-specific antigen assay. The Prostate Health Index (PHI) is a new diagnostic tool that has been described as a good predictor of prostate biopsy outcome. No large study has been performed so far in France. This study aim to evaluate Prostate Health Index diagnostic performances in a large multicentric French cohort of patients undergoing prostate biopsies because of clinical and/or biological suspicion of prostate cancer.

Prostate Health Index will be measured in patients directed to prostate biopsies according to usual practices. Inclusion of 400 patients within 6 months in 12 French centers is expected. The ability of Prostate Health Index to predict prostate cancer at biopsy will be evaluated in terms of intrinsic and extrinsic diagnostic performances including sensitivity, specificity, predictive values, diagnostic accuracy, area under receiver operating curves and decision curve analyses.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-05-11
• Study First Submitted QC: 2017-05-11
• Study First Posted: 2017-05-12
• Study Start: 2017-09-18
• Primary Completion: 2018-09-19
• Study Completion: 2018-10-19
• Status Verified: 2019-08
• Last Update Submitted: 2019-08-12
• Last Update Posted: 2019-08-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 472

Inclusion Criteria

• Man ≥ 18 years old
• Addressed for prostate biopsy because of serum total Prostate Specific Antigen ≥ 4 ng/mL and/or abnormal digital rectal examination and/or first degree familial history of prostate cancer
• Agreeing to participate to the study

Read More

Exclusion Criteria

• Personal history of positive prostate biopsy (evidence of prostate cancer)
• Personal history or evidence of prostate cancer based on clinical data (highly suspicious digital rectal examination (≥cT3) and/or serum total PSA ≥ 20 ng/mL and/or evidence for lymph node or bone metastases (retroperitoneal lymph nodes, bone lesions ...)
• Evidence for synchronous non-prostate cancer (current active treatment)
• Adult protected by law

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients	Measurement of Prostate Health Index (PHI)	Patients addressed for prostate biopsies because of clinical and/or biological suspicion of prostate cancer.

Primary Outcome Measures

Name	Time	Method
Intrinsic performances of Prostate Health Index in predicting prostate biopsy outcome	When the results of all prostate biopsies will be available (approximately at 7 months after the beginning of the study)	Area under receiver operating curve (ROC) analysis; the ROC curve will be constructed from the values of the sensitivity and specificity of Prostate Health Index by comparison to the gold standard, i.e. prostate biopsy outcome (cancer or not).

Trial Locations

Locations (10)

CHU Mondor; 🇫🇷 Créteil, France

CHU Kremlin-Bicêtre; 🇫🇷 Le Kremlin-Bicêtre, France

Clinique Louvière de Lille; 🇫🇷 Lille, France

Hôpital Tenon; 🇫🇷 Paris, France

CHU de Rennes; 🇫🇷 Rennes, France

Clinique Atlantis; 🇫🇷 Saint-Herblain, France

Hôpital Edouard Herriot; 🇫🇷 Lyon, France

Clinique Beau Soleil; 🇫🇷 Montpellier, France

Unité Médicale d'Oncologie et de Transfert - Service de Biochimie et Biologie Moléculaire - Centre Hospitalier Lyon-Sud; 🇫🇷 Pierre-Bénite, France

IUCT Oncopole de Toulouse; 🇫🇷 Toulouse, France